RPV

MariaDB Reaches Agreement to Amend Senior Secured Promissory Note

Retrieved on: 
Thursday, January 11, 2024
Networks, Internet, Data Management, Technology, Software, 8-K, RPV, MariaDB, Security (finance), Finance

MariaDB plc (NYSE:MRDB) today announced that the $26.5 million senior secured promissory note entered into with RP Ventures LLC (“the RPV Note”) that was due January 10, 2024, has been amended, and the RPV Note will now expire on January 31, 2024.

Key Points: 
  • MariaDB plc (NYSE:MRDB) today announced that the $26.5 million senior secured promissory note entered into with RP Ventures LLC (“the RPV Note”) that was due January 10, 2024, has been amended, and the RPV Note will now expire on January 31, 2024.
  • Further details on this transaction can be found on MariaDB’s most recently filed 8-K, which is available on the Securities & Exchange Commission’s (SEC’s) website at https://www.sec.gov and on MariaDB’s Investor Relations website at https://investors.mariadb.com under Financials.

Tonix Pharmaceuticals’ Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

Retrieved on: 
Thursday, November 2, 2023
Monkeypox virus, FDA, National Institute of Allergy and Infectious Diseases, HHS, Food, Therapy, Vaccine, SARS-CoV-2, NIAID, Face, Mpox, Project, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Volunteering, Tonix Pharmaceuticals, Clinical trial, COVID-19, Smallpox, Nextgen, Animal, RPV, NIH, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Infection, Tuberculosis, Bangladesh Technical Education Board

CHATHAM, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), will conduct a Phase 1 clinical trial with TNX-1800 (recombinant horsepox virus, live vaccine),1 Tonix Pharmaceuticals’ vaccine candidate to protect against COVID-19.

Key Points: 
  • Tonix is developing a novel vaccine platform initially targeting COVID-19, smallpox and mpox (monkeypox).
  • The intent is to provide durable protection against severe disease and prevent forward transmission, primarily by eliciting a T-cell immune response.
  • “TNX-1800 will be the first vaccine candidate using our live virus recombinant pox virus (RPV) platform technology to enter clinical trials.
  • NIAID will be conducting clinical trials to evaluate several early-stage vaccine candidates.

GroupBy Enhances its Next-Generation Search and Product Discovery Platform to Improve Performance and Usability for Enterprise eCommerce Retailers and Wholesalers

Retrieved on: 
Thursday, August 10, 2023
Security, Retail, Software, Artificial Intelligence, Internet, Online Retail, Electronic Commerce, Professional Services, Department Stores, Technology, Search Engine Optimization, Search Engine Marketing, Digital Marketing, Data Analytics, Marketing, Other Retail, Communications, Apps, Applications, Cloud, Software as a service, AIS, SSO, RPV, Single sign-on, Command center, E-commerce, AOV, Machine learning, AI, Filter, Automation, Online shopping, OAuth

GroupBy Inc. , a SaaS-based B2C and B2B eCommerce product discovery and search leader, announced today a series of product enhancements that make it easier than ever for retailers to create outstanding product discovery experiences.

Key Points: 
  • GroupBy Inc. , a SaaS-based B2C and B2B eCommerce product discovery and search leader, announced today a series of product enhancements that make it easier than ever for retailers to create outstanding product discovery experiences.
  • GroupBy’s Enrich augments, corrects and normalizes eCommerce product data to improve shopper experiences, product findability and search metrics, while increasing average order value (AOV) and revenue per visitor (RPV).
  • GroupBy’s Enrich product is now located in the Command Center, allowing retailers to view, enhance, and curate their product data in the same space as they perform all of their other vital product discovery functions.
  • This change consolidates the entire GroupBy product suite into one platform, while also improving product data enrichment workflows and overall merchandiser productivity.

Tonix Pharmaceuticals Presents Data from its Vaccine Development Program at the World Vaccine Congress

Retrieved on: 
Thursday, April 6, 2023
Vaccine, RPV, SARS-CoV-2, COVID-19, Mpox, Infection, History, Pandemic, Science, Animal, Virulence, Tonix Pharmaceuticals, Smallpox, Orthopoxvirus

CHATHAM, N.J., April 06, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, presented data from its live virus vaccine platform development program in two oral presentations at the World Vaccine Congress being held in Washington D.C., April 3-6, 2023. Copies of the Company’s presentations are available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.

Key Points: 
  • CHATHAM, N.J., April 06, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, presented data from its live virus vaccine platform development program in two oral presentations at the World Vaccine Congress being held in Washington D.C., April 3-6, 2023.
  • Copies of the Company’s presentations are available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com .
  • “Our lead vaccine candidate, TNX-801, is a live virus vaccine in development to protect against monkeypox (‘mpox’) and smallpox.
  • TNX-1800 is an example of the ability of Tonix’s adaptable vaccine platform to protect against emerging threats and future pandemics.

Tonix Pharmaceuticals Announces Pipeline Prioritization Update for 2023

Retrieved on: 
Tuesday, April 4, 2023
Long COVID, Polyphagia, Prader–Willi syndrome, Psychiatry, Acute stress disorder, Migraine, Interim, Central nervous system, Failure, Therapy, RPV, COVID-19, Infection, Cancer, Smallpox, SL, Disease, Research, COVID, Risk, Autoimmunity, CNS, Government, Pain, Breakthrough therapy, Hydrogen chloride, Orphan drug, MDD, DSM-IV codes, Patient, Annual report, Neurology, Long, Security (finance), PWS, FDA, IND, CD40L, PTSD, Nursing, Pharmaceutical industry, Vaccine, CD154, Depression, Tonix Pharmaceuticals, Fibromyalgia

CHATHAM, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced it is reallocating resources and cash to streamline its pipeline and focus on its mid- and late-stage clinical programs within its core central nervous system (CNS) portfolio. The pipeline realignment prioritizes key near-term value drivers, reduces investment in several longer-term programs, particularly COVID-19-related studies, and delays the start of a posttraumatic stress disorder (PTSD) study in Kenya.

Key Points: 
  • Interim analysis results of Phase 2 PREVENTION study of TNX-1900 (intranasal potentiated oxytocin) for chronic migraine in the fourth quarter of 2023.
  • Interim analysis results of Phase 2 UPLIFT study of TNX-601 ER (tianeptine hemioxalate extended-release tablets) for major depressive disorder in the fourth quarter of 2023.
  • Topline results of Phase 3 RESILIENT study of TNX-102 SL for fibromyalgia in the fourth quarter of 2023.
  • Tonix does not undertake an obligation to update or revise any forward-looking statement.

Unmanned Ground Vehicles Market Report 2022: Rapid Adoption of Autonomous Systems in Defense and Commercial Sectors Fuels Growth

Retrieved on: 
Friday, April 7, 2023
Intelligence, SLAM, Theft, Human, Travel, UGV Interoperability Profile, DARPA, Satellite navigation, CBRN, T4, Rheinmetall, GNSS, RPV, Law enforcement, Star Patrol Mission Master Pack, ARV, ISR, L3Harris Technologies, Build automation, EOD, UGV, Research, USD, XM1219 Armed Robotic Vehicle, S series, Internet, Disaster, Improvised explosive device, Application, Risk, Police, Machine learning, Dog, Map, Tyndall Air Force Base, Simultaneous localization and mapping, Artificial intelligence, Observation, Growth, Weather, Hacking, Mobility, Transport, Commercial, Environment, Complex, Safety, Software, Shipbuilding, Surveying, Satellite navigation device, Reconnaissance, Surveillance, AFB

The market growth is being driven by the increasing adoption of autonomous systems in both commercial and defense sectors, as well as the development of UGV payloads for combat operations and the growing demand for autonomous control systems.

Key Points: 
  • The market growth is being driven by the increasing adoption of autonomous systems in both commercial and defense sectors, as well as the development of UGV payloads for combat operations and the growing demand for autonomous control systems.
  • Autonomous Unmanned Ground Vehicles (UGVs) are typically utilized in challenging terrain, harsh environments, or areas that are inaccessible to humans, significantly reducing the risk of injury to defense personnel.
  • To improve the safety of forces on the battlefield, research and development efforts are underway to design and construct autonomous unmanned defense systems and vehicles.
  • The global unmanned ground vehicle market is segmented based on navigation systems into payloads, navigation systems, controller systems, power systems, and others.

BWXT Awarded Engineering Contract from GE Hitachi for BWRX-300 Small Modular Reactor

Retrieved on: 
Tuesday, March 21, 2023
Engineering, Other Energy, Utilities, Manufacturing, Energy, Other Manufacturing, Nuclear, GEH, SMR, BWXT, RPV, Uranium mining

The RPV, which contains the reactor core and associated internals, comprises the largest component within the BWRX-300.

Key Points: 
  • The RPV, which contains the reactor core and associated internals, comprises the largest component within the BWRX-300.
  • Work associated with the contract includes engineering analysis, design support, manufacturing and procurement preparations.
  • “Intricate design projects like the RPV for GEH’s BWRX-300 are well-suited for BWXT’s engineering capabilities, as BWXT excels in supplying design solutions for complex nuclear components that BWXT can efficiently manufacture,” said John MacQuarrie, president of BWXT Commercial Operations.
  • “We are grateful to GEH for their confidence in our experience and are thrilled to be one of the first to execute an SMR design contract for a North American deployment.”

Terranea Housekeepers Launch Voter Initiative for Fair Pay and Legal Protections Against Sexual Assault on International Women’s Day with UNITE HERE Local 11

Retrieved on: 
Thursday, March 9, 2023
Restaurant, Bar, Professional Services, Consumer, State, Local, Lodging, Public Policy, Travel, Retail, Labor, Women, Human Resources, Government, City, Feminist Majority Foundation, RPV, UNITE, Airport, Weeping Angel, Woman, Oklahoma Labor Commissioner, Panic, Lowe, Tourism, COVID-19, California Democratic Party, Los Angeles Times, Dignity, University, Community, Traction, California Democratic Party v. Jones, Hotel, Erigeron

Undeterred, the resort’s housekeepers and their community allies are returning to finally win the legal rights they have been demanding for years.

Key Points: 
  • Undeterred, the resort’s housekeepers and their community allies are returning to finally win the legal rights they have been demanding for years.
  • RPV should follow the many other cities that have enacted laws guaranteeing housekeepers get fair pay for their work and protections against threatening conduct,” said Nico Gardner-Serna, a member of the Rancho Palos Verdes community.
  • The Office of the Labor Commissioner, led by Lilia Garcia-Brower, investigated complaints from workers alleging violations of the recall law.
  • UNITE HERE Local 11 is a labor union representing over 32,000 hospitality workers in Southern California and Arizona who work in hotels, restaurants, universities, convention centers, and airports
    View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005838/en/

NuScale Power Places First Long Lead Material Production Order with Doosan Enerbility

Retrieved on: 
Thursday, March 9, 2023
Nuclear, Energy, Other Energy, Carbon, SMR, NYSE, Plant, RPV, Multimedia, NuScale Power, NRC, Climate, LLM, Doosan Enerbility, Renewable energy, Doosan Group

NuScale Power Corporation (NYSE: SMR), the industry-leading provider of proprietary and innovative advanced nuclear small modular reactor (SMR) technology, today announced that at the end of 2022, as scheduled, it placed the first upper reactor pressure vessel (RPV) long lead material (LLM) production order with Doosan Enerbility (Doosan), a world-class manufacturing and engineering company.

Key Points: 
  • NuScale Power Corporation (NYSE: SMR), the industry-leading provider of proprietary and innovative advanced nuclear small modular reactor (SMR) technology, today announced that at the end of 2022, as scheduled, it placed the first upper reactor pressure vessel (RPV) long lead material (LLM) production order with Doosan Enerbility (Doosan), a world-class manufacturing and engineering company.
  • The order is for materials essential to commence manufacturing of the first NuScale Power Modules that are scheduled to be in commercial operation at the Utah Associated Municipal Power Systems’ Carbon Free Power Project as early as 2029.
  • In addition, NuScale and Doosan are aligned to manufacture additional modules for future NuScale VOYGR™ SMR power plant projects with similar delivery dates.
  • Building on this completion, the new LLM order includes heavy forgings, steam generator tubes, and weld material for six upper RPVs.

Tonix Pharmaceuticals Announces New Board Member, R. Newcomb Stillwell

Retrieved on: 
Thursday, February 23, 2023
Harvard Law School, Smallpox, Prader–Willi syndrome, DSM-IV codes, Central nervous system, Cancer, Annual report, SL, Pain, Autoimmunity, RPV, Psychiatry, Drug development, Long COVID, Partner, Disease, Research, Neurology, FDA, Ropes & Gray, CNS, Security (finance), COVID-19, Therapy, Rope, Government, CD40L, Risk, Orphan drug, Equity (finance), Mpox, Failure, Princeton University, Infection, Fibromyalgia, MDD, Breakthrough therapy, Hydrogen chloride, Management, Pharmaceutical industry, Tonix Pharmaceuticals, CD154

CHATHAM, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of R. Newcomb Stillwell to its Board of Directors, to be effective as of March 15, 2023.

Key Points: 
  • CHATHAM, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of R. Newcomb Stillwell to its Board of Directors, to be effective as of March 15, 2023.
  • “We are pleased to welcome Newcomb to our Board of Directors," said Seth Lederman, M.D., President and Chief Executive Officer of Tonix.
  • Mr. Stillwell received a J.D., cum laude, from Harvard Law School and an A.B., magna cum laude, from Princeton University.
  • Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering.